Stallergenes Greer is a global biopharmaceutical company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy (AIT) products and services.

Stallergenes Greer has over a century of allergen immunotherapy (AIT) experience and expertise. AIT, also known as desensitisation, uniquely alters the natural course of respiratory allergies. AIT is the only therapeutic class capable of modifying the disease progression and potentially preventing the onset of the disease by inducing tolerance in the immune system.

As part of our commitment to help patients live a life beyond allergy, Stallergenes Greer offers a broad portfolio of allergen extracts and a wide range of state-of-the-art therapeutic solutions for children and adults which provide long lasting relief from the burden of allergies. Spanning source materials, routes of administration, cutting-edge delivery mechanisms and finished products, ours is an innovative portfolio of therapeutic solutions designed to improve ease of access and treatment outcomes.